It has a high drug-to-antibody ratio (DAR) of approximately 8:1, as each antibody carries about 8 cytotoxic payload molecules; this, combined with a stable, tumor-selective linker, enables precise delivery of the cytotoxic payload to HER2-overexpressing tumor cells.4 The gene discussed is ERBB2; the disease is neoplasm.